Thrombolytic Agents: Nanocarriers in Targeted Release
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.)...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:f76ee979d4a648bc935a5093c0960f3a |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:f76ee979d4a648bc935a5093c0960f3a2021-11-25T18:27:10ZThrombolytic Agents: Nanocarriers in Targeted Release10.3390/molecules262267761420-3049https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a2021-11-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/22/6776https://doaj.org/toc/1420-3049A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.) have shortcomings, including a short half-life, serious side effects and a lack of targeting, that limit their clinical application. The use of nano-drug delivery systems is expected to address these problems and a variety of approaches, including biological and physical responsive systems, have been explored. In this report, recent advances in the development of targeted nano-drug delivery systems are thoroughly reviewed.Minghua ShenYujiao WangFan HuLinwen LvKui ChenGengmei XingMDPI AGarticlenano-drug delivery systembiological nano-drug delivery systemphysical responsive nano-drug delivery systemOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6776, p 6776 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
nano-drug delivery system biological nano-drug delivery system physical responsive nano-drug delivery system Organic chemistry QD241-441 |
spellingShingle |
nano-drug delivery system biological nano-drug delivery system physical responsive nano-drug delivery system Organic chemistry QD241-441 Minghua Shen Yujiao Wang Fan Hu Linwen Lv Kui Chen Gengmei Xing Thrombolytic Agents: Nanocarriers in Targeted Release |
description |
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.) have shortcomings, including a short half-life, serious side effects and a lack of targeting, that limit their clinical application. The use of nano-drug delivery systems is expected to address these problems and a variety of approaches, including biological and physical responsive systems, have been explored. In this report, recent advances in the development of targeted nano-drug delivery systems are thoroughly reviewed. |
format |
article |
author |
Minghua Shen Yujiao Wang Fan Hu Linwen Lv Kui Chen Gengmei Xing |
author_facet |
Minghua Shen Yujiao Wang Fan Hu Linwen Lv Kui Chen Gengmei Xing |
author_sort |
Minghua Shen |
title |
Thrombolytic Agents: Nanocarriers in Targeted Release |
title_short |
Thrombolytic Agents: Nanocarriers in Targeted Release |
title_full |
Thrombolytic Agents: Nanocarriers in Targeted Release |
title_fullStr |
Thrombolytic Agents: Nanocarriers in Targeted Release |
title_full_unstemmed |
Thrombolytic Agents: Nanocarriers in Targeted Release |
title_sort |
thrombolytic agents: nanocarriers in targeted release |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/f76ee979d4a648bc935a5093c0960f3a |
work_keys_str_mv |
AT minghuashen thrombolyticagentsnanocarriersintargetedrelease AT yujiaowang thrombolyticagentsnanocarriersintargetedrelease AT fanhu thrombolyticagentsnanocarriersintargetedrelease AT linwenlv thrombolyticagentsnanocarriersintargetedrelease AT kuichen thrombolyticagentsnanocarriersintargetedrelease AT gengmeixing thrombolyticagentsnanocarriersintargetedrelease |
_version_ |
1718411172835753984 |